Jason Harris

The addition of pembrolizumab to belantamab mafodotin resulted in a higher overall response rate in patients with relapsed/refractory multiple myeloma than what has been observed with the antibody-drug conjugate alone, according to results from the phase 1/2 DREAMM-4 trial.

Although systemic treatments are utilized for angiosarcoma, an aggressive and rare subset of a rare cancer, the efficacy achieved with these options is not as good as it needs to be. Immunotherapy may be able to address the unmet need for a systemic treatment in this disease.

The American Society of Clinical Oncology and the Association of Community Cancer Centers have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.

Charles M. Perou, PhD, discusses the role of intrinsic tumor subtyping in treatment decisions and outcomes for patients with breast cancer.

The National Comprehensive Cancer Network issued recommendations for providers treating children with brain cancers.

Cabozantinib monotherapy maintained continued to provide a superior progression-free survival benefit to that achieved with placebo in adults with locally advanced or metastatic differentiated thyroid carcinoma, irrespective of histology, according to updated data from the phase 3 COSMIC-311 trial.

CV-01, Alpheus Medical’s novel sonodynamic therapy delivery platform, has received orphan drug and fast track designations from the FDA for the treatment of patients with recurrent glioblastoma.

Despite receiving similar treatment, Black patients between the ages of 18 and 29 years with acute myeloid leukemia were twice as likely to die within 5 years compared with Whites.

A 3-month course of oxaliplatin produced disease-free survival noninferior to a 6-month course in patients with high-risk stage II and III colorectal cancer.

Enfortumab vedotin extended overall survival by 3.97 months compared with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

Disitamab vedotin demonstrated promising efficacy with a tolerable safety profile in patients with HER2-negative metastatic urothelial carcinoma.

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

The addition of orelabrutinib to sintilimab demonstrated good efficacy with a rapid time to response in patients with relapsed/refractory primary central nervous system lymphoma.

Among men in the United States, incidence-based mortality is growing for penile cancer even though incidence remained consistent from 2000 to 2018.

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

A supplemental New Drug Application has been submitted to Japan’s Ministry of Health, Labour, and Welfare seeking approval for use of trastuzumab deruxtecan for the treatment of adult patients with HER2-low unresectable or recurrent metastatic breast cancer following chemotherapy

“Compelling” data support the use of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer and the use of sacituzumab govitecan for patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

The US Preventive Services Task Force updated its lung cancer screening guidelines in 2021 to include more members of vulnerable populations, including African Americans, women, and the LGBTQ community.

The European Medicines Agency has validated a Type II Variation application for trastuzumab deruxtecan as monotherapy for adults with unresectable or metastatic HER2-low breast cancer.

RG6234, a novel T-cell engaging bispecific antibody with a 2:1 configuration, induced high response rates and early evidence of durability for patients with relapsed/refractory multiple myeloma.

The combination of obinutuzumab plus chemotherapy delivered superior long-term progression-free survival benefit for patients with treatment-naïve follicular lymphoma.

Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia assigned to zanubrutinib reported better health-related quality of life than those administered ibrutinib.

The FDA has given the green light to FoundationOne CDx to identify patients with ROS1 fusion–positive non–small cell lung cancer or NTRK fusion–positive cancers who might be candidates for entrectinib.

Neoadjuvant nivolumab in combination with platinum-based doublet chemotherapy extended event-free survival in patients with stage IB-IIA non–small cell lung cancer who had pathologic complete response, according to a post hoc analysis of the phase 3 CheckMate 816 trial.

Patritumab deruxtecan produced encouraging responses in patients with HER3-expressing metastatic breast cancer or metastatic triple negative breast cancer.

The combination of the humanized anti-GD2 antibody naxitamab-gqgk, irinotecan, temozolomide, and sargramostim met its primary end point for objective response rate in patients with chemoresistant high-risk neuroblastoma.

The FDA announced that it has withdrawn approval for umbralisib, an oral inhibitor of PI3K-δ and CK1-ε manufactured by TG Therapeutics.

Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival rates compared with other children.

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance recommending the approval of pembrolizumab plus chemotherapy for the treatment of patients with PD-L1–positive metastatic triple-negative breast cancer.

The American Urologic Association in collaboration with the American Society for Radiation Oncology has issued new practice guidelines for the management of clinically localized prostate cancer.